1. Home
  2. CRDF vs CXE Comparison

CRDF vs CXE Comparison

Compare CRDF & CXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.63

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Logo MFS High Income Municipal Trust

CXE

MFS High Income Municipal Trust

HOLD

Current Price

$3.74

Market Cap

118.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRDF
CXE
Founded
1999
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
130.7M
118.2M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
CRDF
CXE
Price
$1.63
$3.74
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$9.63
N/A
AVG Volume (30 Days)
628.6K
68.9K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
4.36%
EPS Growth
27.37
N/A
EPS
N/A
0.07
Revenue
$365,993.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$53.71
Revenue Growth
49.61
N/A
52 Week Low
$1.48
$3.40
52 Week High
$4.56
$3.88

Technical Indicators

Market Signals
Indicator
CRDF
CXE
Relative Strength Index (RSI) 45.27 46.25
Support Level $1.51 $3.66
Resistance Level $1.68 $3.76
Average True Range (ATR) 0.08 0.04
MACD 0.01 0.01
Stochastic Oscillator 38.46 64.36

Price Performance

Historical Comparison
CRDF
CXE

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

About CXE MFS High Income Municipal Trust

Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company's investment portfolio has shares from the industry Healthcare, Airports, and Secondary Schools.

Share on Social Networks: